Literature DB >> 16280756

The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.

Atsushi Ochiai1, Patricia Troncoso, Michael E Chen, Joseph Lloreta, R Joseph Babaian.   

Abstract

PURPOSE: We assessed the relationship between the number of positive cores obtained at extended biopsy and tumor volume in radical prostatectomy specimens as a tool for predicting the biological significance of prostate cancer from biopsy data.
MATERIALS AND METHODS: The study group included 207 men who were treated with radical prostatectomy without neoadjuvant therapy at our cancer center. All patients were diagnosed by systematic extended biopsy (10 or 11 cores) performed between 1997 and 2003. The variables analyzed were patient age, prostate specific antigen, clinical stage, biopsy Gleason score, maximum tumor length in a core, greatest percent of tumor in a core, total tumor length, total percent of tumor in all cores, positive core location, initial or repeat biopsy and prostate volume in subgroups based on the number of positive cores, that is group 1-1, group 2-2 and group 3-3 or more cores. Bivariate correlation analysis and multiple logistic regression analysis were used to determine the predictors of insignificant cancer.
RESULTS: The number of positive cores was significantly related to total tumor volume (r = 0.433, p <0.001). Insignificant prostate cancer (volume less than 0.5 cc and Gleason score 6 or less) was found in 21.7% of patients (45 of 207). The incidence of insignificant cancer was 42.5% (31 of 73 patients) in group 1, 16.4% (10 of 61) in group 2 and 5.5% (4 of 73) in group 3. There was a significant difference in the incidence of insignificant cancer among the subgroups (group 1 vs 2 p <0.001, group 1 vs 3 p <0.0001 and group 2 vs 3 p <0.05). The best model for predicting insignificant cancer in group 1 was the combination of tumor length less than 2 mm, Gleason score 3 + 4 or less and prostate volume greater than 50 cc with 83.9% sensitivity (26 of 31 patients) and 61.9% specificity (26 of 42).
CONCLUSIONS: The probability of insignificant cancer was directly related to the number of positive cores. Tumor length in a core, Gleason score and prostate volume significantly enhanced the prediction model for insignificant cancer in men with 1 positive core who underwent extended biopsy.

Entities:  

Mesh:

Year:  2005        PMID: 16280756     DOI: 10.1097/01.ju.0000181211.49267.43

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

2.  Exponential apparent diffusion coefficient in evaluating prostate cancer at 3 T: preliminary experience.

Authors:  Sung Y Park; Chan K Kim; Jung J Park; Byung K Park
Journal:  Br J Radiol       Date:  2015-12-10       Impact factor: 3.039

3.  Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.

Authors:  Chinonyerem Okoro; Arvin K George; M Minhaj Siddiqui; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Nabeel A Shakir; Jason T Rothwax; Dima Raskolnikov; Lambros Stamatakis; Daniel Su; Baris Turkbey; Peter L Choyke; Maria J Merino; Howard L Parnes; Bradford J Wood; Peter A Pinto
Journal:  J Endourol       Date:  2015-07-23       Impact factor: 2.942

4.  Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.

Authors:  John W Davis; John F Ward; Curtis A Pettaway; Xuemei Wang; Deborah Kuban; Steven J Frank; Andrew K Lee; Louis L Pisters; Surena F Matin; Jay B Shah; Jose A Karam; Brian F Chapin; John N Papadopoulos; Mary Achim; Karen E Hoffman; Thomas J Pugh; Seungtaek Choi; Patricia Troncoso; Christopher J Logothetis; Jeri Kim
Journal:  BJU Int       Date:  2015-07-04       Impact factor: 5.588

5.  [Clinical insignificance of prostate cancer: are there morphological findings?].

Authors:  B Helpap; L Egevad
Journal:  Urologe A       Date:  2009-02       Impact factor: 0.639

6.  Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings.

Authors:  Philip Quann; David F Jarrard; Wei Huang
Journal:  Int J Clin Exp Pathol       Date:  2010-03-30

7.  Significance of predicted tumor volume as a predictor of pathologic stage in patients undergoing radical prostatectomy.

Authors:  Ja Hyeon Ku; Kyung Chul Moon; Cheol Kwak; Hyeon Hoe Kim
Journal:  Korean J Urol       Date:  2011-01-24

8.  Prostate cancer--to screen, or not to screen, is that the question?

Authors:  Charles J Rosser
Journal:  BMC Urol       Date:  2008-12-23       Impact factor: 2.264

9.  Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort.

Authors:  Justin R Gregg; John W Davis; Chad Reichard; Xuemei Wang; Mary Achim; Brian F Chapin; Louis Pisters; Curtis Pettaway; John F Ward; Seungtaek Choi; Quynh-Nhu Nguyen; Deborah Kuban; Richard Babaian; Patricia Troncoso; Lydia T Madsen; Christopher Logothetis; Jeri Kim
Journal:  Urology       Date:  2019-12-30       Impact factor: 2.649

10.  International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy.

Authors:  L-M Wong; D E Neal; R B Johnston; N Shah; N Sharma; A Y Warren; C M Hovens; S Larry Goldenberg; M E Gleave; A J Costello; N M Corcoran
Journal:  Br J Cancer       Date:  2012-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.